Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced to optimize study design in alignment with IMG-007’s unique molecular attributes; strong patient ...
$142.6 million cash and cash equivalents and marketable securities as of September 30, 2025 Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback